A leading independent European specialty pharmaceutical company
[i] Blachier M, Leleu H, Peck-Radosavljevic et al. The burden of liver disease in Europe. A review of available epidemiological data. EASL, 2013
[iii] Orr J.G. et al. Resource use associated with hepatic encephalopathy in patients with liver disease. International Liver Congress 2014, Abstract P478
P. Stein, CEO: "New collaboration with @Accesspharma is evidence of Norgine’s commitment to acquire further speciality pharma products"
We are committed to the management of hepatic encephalopathy, a chronic condition of the liver http://t.co/T691JDCBhP